Height and Weight Can Influence Lymphoma Risk in Teens

A new study published in CANCER reveals that height and body weight during adolescence can impact the risk of developing non-Hodgkin's lymphoma (NHL).

Specifically, a higher body weight and taller stature increase the odds of developing NHL - which is one of the most common forms of cancer found in children.

"It is important to be aware that overweight and obesity are not risk factors only for diabetes and cardiovascular disease but also for lymphomas," said Dr. Merav Leiba, from the Sheba Medical Center in Israel.

Excess nutrition may impact growth factors

The study suggests that higher obesity rates could contribute to the growing presence of NHL, but this does not explain why height is associated with risk for the disease.

Researchers looked at data on over 2 million teens between the ages of 16 and 19, finding there was a gradient in NHL risk with increasing height. Shorter teens had a 25 percent lower risk of NHL, while the tallest study participants had a 28 percent increased risk.

"As for mechanism, height and excess nutrition in childhood may have impacts on inflammatory molecules and growth factors that could support the development of NHL, but additional studies are needed to investigate these possibilities," a news release on the study stated.

Source: WILEY

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap